Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Cir Pediatr ; 32(1): 41-45, 2019 Jan 21.
Artículo en Español | MEDLINE | ID: mdl-30714700

RESUMEN

INTRODUCTION: High morbidity has been described in secondary chylothorax. Thoracic duct embolization (TDE) after intranodal lymphangiography (IL) is one of the treatments in adults but there is poor experience in children. We aim to describe our experience with this technique for refractory pediatric chylothorax. METHODS: A retrospective study of patients with refractory chylothorax treated with thoracic duct embolization at our Institution in the last 4 years was performed. Lymphatic vessels visualization was obtained by intranodal lymphangiography with ethiodized oil. Demographic and clinical data as well as imaging findings were collected. RESULTS: A total of 4 patients were treated during the study period with a median of age and weight of 2.5 months (1-16) and 4.25 kg (2.8-10) respectively. Chylothorax was secondary to cardiothoracic surgery in 3 patients and to venous thrombosis in the other one. Medical treatment was provided during a median of 47 days (13-56) without benefit in thoracic output [median: 46 ml/kg/day (19-64)]. After IL, thoracic duct catheterization was achieved in one patient however embolization was not possible. Chylothorax stopped in the 3 post-surgical patients regardless of how much lymphatic visualization was achieved in IL. In the venous thrombosis patient surgical treatment was performed 6 days after the study. CONCLUSION: IL can be a diagnostic and therapeutic tool in children. Ethiodized oil seems to seal lymphatic leak in postsurgical chylothorax. IL could be an option for chylothorax in patients too sick for surgical treatment or in whom thoracic duct embolization is not feasible.


INTRODUCCION: El quilotórax secundario es una entidad rara con una alta morbilidad. La embolización del conducto torácico (CT) mediante linfangiografía intranodal (LI) con aceite etiodizado (AE) forma parte del arsenal terapéutico del quilotórax en el adulto. Presentamos nuestra experiencia con esta técnica en pacientes pediátricos con quilotórax refractario al tratamiento médico. METODOS: Estudio retrospectivo de los pacientes tratados en nuestro centro por quilotórax refractario con LI en los últimos 4 años. Se recogieron los datos epidemiológicos, clínicos, terapéuticos y linfangiográficos. RESULTADOS: Se identificaron 4 pacientes, con unas medianas de edad y peso de 2,5 meses (1-16) y 4,25 kg (2,8-10) respectivamente. En 3 de los pacientes el quilotórax fue secundario a cirugía cardiaca y en el restante a trombosis extensa de vena cava superior. La mediana de débito fue de 46 ml/kg/día (19-64) y la de tiempo de tratamiento médico de 47 días (13-56). En todos ellos se realizó LI, opacificándose el CT solo en un paciente, sin lograrse la embolización. A pesar de ello, tras la LI, el quilotórax cesó en el grupo postquirúrgico independientemente del nivel de opacificación del árbol linfático. En el paciente secundario a trombosis, se realizó ligadura quirúrgica del CT 6 días después del estudio. CONCLUSIONES: La LI es una técnica diagnóstica e incluso terapéutica en casos de quilotórax refractario, que comienza a ser necesaria y realizable en centros con experiencia. El AE parece sellar la fuga linfática por un mecanismo embolizante en casos postquirúrgicos, eliminando la necesidad del cierre quirúrgico.


Asunto(s)
Quilotórax/terapia , Embolización Terapéutica/métodos , Linfografía/métodos , Conducto Torácico/diagnóstico por imagen , Quilotórax/diagnóstico por imagen , Quilotórax/etiología , Aceite Etiodizado/administración & dosificación , Humanos , Lactante , Complicaciones Posoperatorias/diagnóstico por imagen , Complicaciones Posoperatorias/terapia , Estudios Retrospectivos , Resultado del Tratamiento , Trombosis de la Vena/complicaciones
2.
Cir. pediátr ; 29(3): 110-114, jul. 2016. tab, graf
Artículo en Español | IBECS | ID: ibc-161404

RESUMEN

Introducción/Objetivo. En la literatura actual existe debate en cuanto a la necesidad de ingresar a los pacientes con invaginación intestinal (II) después de la reducción exitosa mediante enema. El propósito de este estudio es caracterizar la recidiva de las II en nuestro medio para valorar la posibilidad del tratamiento ambulatorio. Pacientes y métodos. Estudio retrospectivo de los niños atendidos por II entre 2009 y 2013 definiendo como recidiva temprana la que ocurre entre las 12-72 horas post-reducción, comparando los resultados con la literatura actual. Resultados. Se trataron 121 niños (77 varones - 44 mujeres), con edad de 18,9±2,7 meses y peso de 10,77±0,57 kg (IC 95%), por II. Se intentó reducción mediante enema en 90,7% (n= 88) de los casos, siendo efectivo en un 76,1% (n= 67). La tasa de recidiva temprana fue del 6% (n= 4), sin complicaciones asociadas, similar a lo referido en estudios de meta-análisis recientes (5,4%); tres precisaron tratamiento quirúrgico. La estancia hospitalaria media es de 2 días para las II tratadas conservadoramente, lo que supuso un gasto promedio de 2.076,67 euros por ingreso. Conclusión. Dada la baja tasa de recidiva temprana y escaso riesgo de complicaciones, la observación durante 8-12 horas es una alternativa al ingreso hospitalario, lo que conllevaría ventajas de bienestar socio-familiar y de gestión. Estos resultados sirven como punto de partida para estudios prospectivos randomizados entre ambas modalidades de tratamiento


Introduction/Purpose. There is current debate about the need of hospitalization of patients with enema-reduced intussusception. The purpose of this study is to describe intussusception recurrence in a tertiary care children’s hospital in order to evaluate the feasibility of ambulatory treatment. Patients and methods. Retrospective review of children diagnosed with intussusception from January 2009 to December 2013, identifying early recurrences as those that occurred between 12-72 hours after successful enema reduction and comparing the results with current literature. Results. A total of 121 children (77 male - 44 female), with a mean age of 18,9±2,7 months and weight of 10,77±0,57 kg (CI 95%) were treated for intussusception. Enema reduction was attempted in 90,7% (n= 88) of the cases, with a success rate of 76,1% (n= 67). Early recurrence rate was 6% (n= 4), without associated complications, which is similar to recent meta-analysis results (5,4%); however, three patients required surgical exploration. Mean length of stay was 2 days for enema-reduced intussusception, which resulted in a total cost of 2,076.67 euro per patient. Conclusion. The low recurrence rate and scarce risk of complications suggests that an 8 to 12 hour observation is a feasible alternative to hospital admission, which results in social advantages including family welfare as well as management costs. These results are a starting point for prospective randomized controlled trials comparing both treatment modalities


Asunto(s)
Humanos , Niño , Intususcepción/cirugía , Procedimientos Quirúrgicos Ambulatorios/estadística & datos numéricos , Recurrencia , Alta del Paciente/estadística & datos numéricos , Complicaciones Posoperatorias/epidemiología , Presión Hidrostática
3.
Cir Pediatr ; 29(3): 110-114, 2016 Jul 10.
Artículo en Español | MEDLINE | ID: mdl-28393505

RESUMEN

INTRODUCTION/PURPOSE: There is current debate about the need of hospitalization of patients with enema-reduced intussusception. The purpose of this study is to describe intussusception recurrence in a tertiary care children's hospital in order to evaluate the feasibility of ambulatory treatment. PATIENTS AND METHODS: Retrospective review of children diagnosed with intussusception from January 2009 to December 2013, identifying early recurrences as those that occurred between 12-72 hours after successful enema reduction and comparing the results with current literature. RESULTS: A total of 121 children (77 male - 44 female), with a mean age of 18,9±2,7 months and weight of 10,77±0,57 kg (CI 95%) were treated for intussusception. Enema reduction was attempted in 90,7% (n= 88) of the cases, with a success rate of 76,1% (n= 67). Early recurrence rate was 6% (n= 4), without associated complications, which is similar to recent meta-analysis results (5,4%); however, three patients required surgical exploration. Mean length of stay was 2 days for enema-reduced intussusception, which resulted in a total cost of 2,076.67 euro per patient. CONCLUSION: The low recurrence rate and scarce risk of complications suggests that an 8 to 12 hour observation is a feasible alternative to hospital admission, which results in social advantages including family welfare as well as management costs. These results are a starting point for prospective randomized controlled trials comparing both treatment modalities.


INTRODUCCION/OBJETIVO: En la literatura actual existe debate en cuanto a la necesidad de ingresar a los pacientes con invaginación intestinal (II) después de la reducción exitosa mediante enema. El propósito de este estudio es caracterizar la recidiva de las II en nuestro medio para valorar la posibilidad del tratamiento ambulatorio. PACIENTES Y METODOS: Estudio retrospectivo de los niños atendidos por II entre 2009 y 2013 definiendo como recidiva temprana la que ocurre entre las 12-72 horas post-reducción, comparando los resultados con la literatura actual. RESULTADOS: Se trataron 121 niños (77 varones - 44 mujeres), con edad de 18,9±2,7 meses y peso de 10,77±0,57 kg (IC 95%), por II. Se intentó reducción mediante enema en 90,7% (n= 88) de los casos, siendo efectivo en un 76,1% (n= 67). La tasa de recidiva temprana fue del 6% (n= 4), sin complicaciones asociadas, similar a lo referido en estudios de meta-análisis recientes (5,4%); tres precisaron tratamiento quirúrgico. La estancia hospitalaria media es de 2 días para las II tratadas conservadoramente, lo que supuso un gasto promedio de 2.076,67 euros por ingreso. CONCLUSION: Dada la baja tasa de recidiva temprana y escaso riesgo de complicaciones, la observación durante 8-12 horas es una alternativa al ingreso hospitalario, lo que conllevaría ventajas de bienestar socio-familiar y de gestión. Estos resultados sirven como punto de partida para estudios prospectivos randomizados entre ambas modalidades de tratamiento.


Asunto(s)
Atención Ambulatoria , Enema/estadística & datos numéricos , Intususcepción/terapia , Tiempo de Internación , Alta del Paciente , Estudios de Factibilidad , Femenino , Hospitales Pediátricos , Humanos , Lactante , Masculino , Estudios Prospectivos , Recurrencia , Estudios Retrospectivos , Centros de Atención Terciaria , Factores de Tiempo , Resultado del Tratamiento
4.
Neurología (Barc., Ed. impr.) ; 28(2): 81-87, mar. 2013. ilus, tab
Artículo en Español | IBECS | ID: ibc-110230

RESUMEN

Introducción: Las psicosis epilépticas se dividen respecto de su relación con las crisis en periictales e interictales. Las psicosis periictales tienen una estrecha relación temporal con las crisis epilépticas y ocurren antes (preictales), durante (ictales) o después de las mismas (postictales). Generalmente, tienen un inicio y final agudo, corta duración y una remisión completa, con riesgo de recurrencia. Las psicosis interictales o crónicas no guardan relación temporal con las crisis epilépticas. Existe otro tipo de psicosis epilépticas que se relaciona con la respuesta al tratamiento de la epilepsia: psicosis epiléptica por fenómeno de normalización forzada (psicosis alternativa) y dentro de esta se encuentra la psicosis epiléptica secundaria a cirugía de la epilepsia. Aunque se ha generalizado la combinación de antiepilépticos y neurolépticos para su manejo, no existen unas pautas estandarizadas de tratamiento en las psicosis epilépticas. Casos clínicos: Presentamos 5 casos de psicosis epilépticas periictales y remarcamos la excelente respuesta al tratamiento con levetiracetam. Consiguiendo un buen control tanto de las crisis como de los episodios psicóticos. Este fármaco resultó inocuo al asociarlo con neurolépticos en nuestros pacientes y no se precisaron dosis elevadas de estos últimos. Conclusiones: La diferenciación de los estados psicóticos asociados con la epilepsia según la relación temporal con las crisis epilépticas tiene utilidad clínica y pronóstica, dado que aporta aspectos importantes respecto al tratamiento y a la evolución de la enfermedad. El tratamiento de los trastornos mentales periictales o agudos se basa en el control de las crisis epilépticas, mientras que el tratamiento de los interictales o crónicos guarda más similitud con el de los trastornos de origen puramente psiquiátrico. El control estricto de las crisis puede, además de mejorar la calidad de vida del paciente y su discapacidad, prevenir el desarrollo de una psicosis interictal, por lo que consideramos que sería necesario establecer un protocolo de tratamiento para estos casos (AU)


Introduction: Epileptic psychoses are categorised as peri-ictal and interictal according to their relationship with the occurrence of seizures. There is a close temporal relationship between peri-ictal psychosis and seizures, and psychosis may present before (preictal), during (ictal) or after seizures (postictal). Epileptic psychoses usually have acute initial and final phases, with a short symptom duration and complete remission with a risk of recurrence. There is no temporal relationship between interictal or chronic psychosis and epileptic seizures. Another type of epileptic psychosis is related to the response to epilepsy treatment: epileptic psychosis caused by the phenomenon of forced normalisation (alternative psychosis), which includes epileptic psychosis secondary to epilepsy surgery. Although combination treatment with antiepileptic and neuroleptic drugs is now widely used to manage this condition, there are no standard treatment guidelines for epileptic psychosis. Clinical cases: We present 5 cases of peri-ictal epileptic psychosis in which we observed an excellent response to treatment with levetiracetam. Good control was achieved over both seizures and psychotic episodes. Levetiracetam was used in association with neuroleptic drugs with no adverse effects, and our patients did not require high doses of the latter. Conclusions: Categorising psychotic states associated with epilepsy according to their temporal relationship with seizures is clinically and prognostically useful because it provides important information regarding disease treatment and progression. The treatment of peri-ictal or acute mental disorders is based on epileptic seizure control, while the treatment of interictal or chronic disorders has more in common with managing disorders which are purely psychiatric in origin. In addition to improving the patient’s quality of life and reducing disability, achieving strict control over seizures may also prevent the development of interictal psychosis. For this reason, we believe that establishing a treatment protocol for such cases is necessary (AU)


Asunto(s)
Humanos , Masculino , Femenino , Adulto , Epilepsia/complicaciones , Trastornos Psicóticos/etiología , Anticonvulsivantes/uso terapéutico , Calidad de Vida , Resultado del Tratamiento
5.
Clin Microbiol Infect ; 14(7): 691-7, 2008 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-18558942

RESUMEN

The objective of this study was to evaluate the activities of ciprofloxacin and levofloxacin in a murine model of pneumonia caused by Klebsiella pneumoniae C2 (with altered GyrA, deficient in porins and expressing active efflux of quinolones) and the transconjugant C2pMG252 derived from it and expressing the qnrA1 determinant. MICs and MBCs of the two quinolones were determined according to CLSI guidelines. Time-kill curves (at 1x and 4x MIC) were also performed to assess bactericidal activity. An experimental model of pneumonia in mice was evaluated. Groups of 15 mice were infected with either strain and treated with ciprofloxacin (80 mg/kg/day) or levofloxacin (100 mg/kg/day). Control non-treated animals were also evaluated. In the case of strain C2, log(10) CFU/g of lung in non-treated animals was 9.16 +/- 2.16. This value was reduced to 3.53 +/- 1.04 (p <0.001) and 3.38 +/- 0.46 (p <0.001) in animals treated with ciprofloxacin or levofloxacin, respectively. Percentages of surviving mice were 26.7% (control group) and 100% (both ciprofloxacin and levofloxacin; p <0.001 vs. controls). Bacterial counts (log(10) CFU/g) in lungs of animals infected with strain C2pMG252 were 9.65 +/- 2.49 in non-treated animals and 7.74 +/- 2.67 and 7.57 +/- 3.84 for those treated with ciprofloxacin or levofloxacin, respectively (p >0.05 vs. control group). Of non-treated animals infected with strain C2pMG252, 14.3% survived. Ciprofloxacin and levofloxacin improved the survival in these mice (53.3% for both antimicrobials, p 0.03). In conclusion, the expression of qnrA1 in K. pneumoniae with additional mechanisms of resistance causes decreased efficacy of fluoroquinolones in a pneumonia model in mice.


Asunto(s)
Proteínas Bacterianas/biosíntesis , Ciprofloxacina/uso terapéutico , Infecciones por Klebsiella/tratamiento farmacológico , Klebsiella pneumoniae/efectos de los fármacos , Klebsiella pneumoniae/crecimiento & desarrollo , Levofloxacino , Ofloxacino/uso terapéutico , Neumonía Bacteriana/tratamiento farmacológico , Animales , Antibacterianos/farmacocinética , Antibacterianos/uso terapéutico , Ciprofloxacina/farmacocinética , Recuento de Colonia Microbiana , Farmacorresistencia Bacteriana , Femenino , Ratones , Ratones Endogámicos C57BL , Pruebas de Sensibilidad Microbiana , Ofloxacino/farmacocinética , Porinas/metabolismo
6.
Clin Microbiol Infect ; 14(6): 582-7, 2008 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18294246

RESUMEN

The algorithms included in most automated systems used for antimicrobial susceptibility testing (e.g., Vitek 2) consider that Escherichia coli isolates resistant to cefoxitin are AmpC-hyperproducers and, consequently, resistant also to amoxycillin-clavulanate. However, a recent study revealed that 30% of E. coli clinical isolates resistant to cefoxitin remained susceptible in vitro to amoxycillin-clavulanate. The aim of the present study was to evaluate the in-vivo efficacy of amoxycillin-clavulanate in the treatment of an experimental model of pneumonia, using two clonally related isolates (with identical repetitive extragenic palindromic sequence (REP)-PCR patterns) of AmpC-non-hyperproducing and OmpF-lacking E. coli (Ec985 and Ec571) that were resistant to cefoxitin and susceptible to cefotaxime and amoxycillin-clavulanate. MICs were determined using a microdilution technique, and in-vitro bactericidal activity was tested using time-kill assays. The in-vivo efficacy of amoxycillin, amoxycillin-clavulanate and cefotaxime against both isolates was tested in a murine pneumonia model using immunocompetent C57BL/6 mice. Ec571 (a TEM-1/2 producer) was resistant to amoxycillin, whereas Ec985 (a TEM-1/2 non-producer) was susceptible. Amoxycillin, amoxycillin-clavulanate and cefotaxime were bactericidal for Ec985, and amoxycillin-clavulanate and cefotaxime were bactericidal for Ec571 at different concentrations and time-points, as determined using time-kill assays. Treatment with amoxycillin, amoxycillin-clavulanate and cefotaxime reduced the bacterial lung concentration of Ec985 compared with non-treated controls (p <0.05), whereas amoxycillin-clavulanate and cefotaxime showed efficacy against Ec571 when compared with the control and amoxycillin groups (p <0.05). Regardless of the exact underlying mechanism(s) of resistance, amoxycillin-clavulanate was effective in the experimental murine model in the treatment of pneumonia caused by AmpC-non-hyperproducing strains of E. coli resistant to cefoxitin.


Asunto(s)
Combinación Amoxicilina-Clavulanato de Potasio/uso terapéutico , Proteínas Bacterianas/antagonistas & inhibidores , Infecciones por Escherichia coli/tratamiento farmacológico , Escherichia coli/efectos de los fármacos , Neumonía Bacteriana/tratamiento farmacológico , Resistencia betalactámica , Inhibidores de beta-Lactamasas , Amoxicilina/sangre , Amoxicilina/uso terapéutico , Combinación Amoxicilina-Clavulanato de Potasio/farmacocinética , Animales , Antibacterianos/sangre , Antibacterianos/uso terapéutico , Cefotaxima/sangre , Cefotaxima/uso terapéutico , Cefoxitina/farmacología , Quimioterapia Combinada , Escherichia coli/enzimología , Femenino , Pulmón/microbiología , Ratones , Ratones Endogámicos C57BL , Pruebas de Sensibilidad Microbiana , Organismos Libres de Patógenos Específicos , beta-Lactamasas
7.
Clin Microbiol Infect ; 11(1): 31-8, 2005 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-15649301

RESUMEN

The in-vivo activities of cefepime, imipenem and meropenem against the porin-deficient strain Klebsiella pneumoniae C2 and its derivative K. pneumoniae C2(pMG252) coding for the AmpC-type beta-lactamase FOX-5 were determined. Bactericidal activities were determined with the kill-curve method. A pneumonia model in guinea-pigs was developed, and Cmax, t(1/2) and DeltaT/MIC were calculated for the three agents tested. Animals were treated for 72 h with sterile saline (control group) or with cefepime, imipenem or meropenem (240 mg/kg/day, intramuscularly, three times daily). Bacterial counts in lungs (log10 CFU/g tissue) were determined by serial dilution. MICs (mg/L) of cefepime, imipenem and meropenem against K. pneumoniae C2/K. pneumoniae C2(pMG252), determined by macrodilution, were: 0.5/4, 0.5/0.5 and 0.25/0.5, respectively. Bacterial counts in the lungs of animals infected with K. pneumoniae C2 and treated with antimicrobial agents were always lower than in the control group (cefepime, 4.4 +/- 0.5; imipenem, 4.6 +/- 0.4; meropenem, 4.7 +/- 0.5; control group, 5.6 +/- 0.8; p <0.01). No significant differences were observed among the groups receiving therapy (p >0.05). Bacterial lung clearance was higher in treated animals than in control animals following infection with K. pneumoniae C2(pMG252) (cefepime, 4.5 +/- 0.4; imipenem, 4.0 +/- 0.3; meropenem, 4.6 +/- 0.4; control group, 6.1 +/- 0.6; p <0.01), with imipenem producing better clearance than either cefepime or meropenem (p <0.05). Thus, in the guinea-pig pneumonia model, cefepime, imipenem and meropenem were each effective against the porin-deficient K. pneumoniae strain C2 and its derivative expressing the plasmid-mediated AmpC type beta-lactamase FOX-5.


Asunto(s)
Antibacterianos/uso terapéutico , Carbapenémicos/uso terapéutico , Cefalosporinas/uso terapéutico , Klebsiella pneumoniae/efectos de los fármacos , Neumonía Bacteriana/tratamiento farmacológico , beta-Lactamasas/metabolismo , Animales , Antibacterianos/farmacología , Carbapenémicos/farmacocinética , Carbapenémicos/farmacología , Cefepima , Cefalosporinas/farmacocinética , Cefalosporinas/farmacología , Recuento de Colonia Microbiana , Cobayas , Humanos , Imipenem/farmacocinética , Imipenem/farmacología , Imipenem/uso terapéutico , Infecciones por Klebsiella/tratamiento farmacológico , Infecciones por Klebsiella/microbiología , Klebsiella pneumoniae/enzimología , Pulmón/microbiología , Meropenem , Pruebas de Sensibilidad Microbiana , Neumonía Bacteriana/microbiología , Porinas/genética , Tienamicinas/farmacocinética , Tienamicinas/farmacología , Tienamicinas/uso terapéutico , Resultado del Tratamiento , beta-Lactamasas/genética
8.
Cir Pediatr ; 3(2): 45-8, 1990 Apr.
Artículo en Español | MEDLINE | ID: mdl-2252847

RESUMEN

22 patients, divided in 2 groups, are studied under-going intestinal resection as consequence of different pathological entities. Group I of 13 patients who had the ileocecal unión resected. Group II is made up of 9 patients who had small fragments of the small intestine enucleated. All the patients have, among other things, various anthropometrical, hematological and biochemical parameters, and their Ca/P metabolism analyzed, as well as the elimination of urinary nitrogen in its different forms. The patients who underwent resection of the ileocecal union present anthropometrical alterations, which can be consequence of a state of chronic malnutrition. The differences found in the alkaline phosphatase and in the elimination of amino acids in the urine can be a sign of a bacterial contamination of the small intestine by fecal flora or a sign of less availability of energetic contribution.


Asunto(s)
Trastornos del Crecimiento/etiología , Válvula Ileocecal/cirugía , Trastornos Nutricionales/etiología , Complicaciones Posoperatorias , Fosfatasa Alcalina/sangre , Aminoácidos/orina , Calcio/metabolismo , Niño , Trastornos del Crecimiento/metabolismo , Humanos , Intestino Delgado/microbiología , Trastornos Nutricionales/metabolismo , Fósforo/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA